Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Bayer, Orion prep challenge in prostate cancer market

Erleada (apalutamide) and Pfizer/Astellas’ Xtandi (enzalutamide). ... J&J isn’t breaking out Erleada sales yet in its results after its approval in the US for non-metastatic CRPC last year, but has predicted it could grow into

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics